For research use only. Not for therapeutic Use.
FCE 22250(Cat No.:I027325)is a selective serotonin (5-HT) receptor antagonist, primarily targeting the 5-HT3 receptor subtype. It has been investigated for its potential therapeutic applications in treating conditions associated with excessive serotonin activity, such as nausea, vomiting, and certain gastrointestinal disorders. The 5-HT3 receptor is involved in the regulation of gastrointestinal motility and emesis. FCE 22250 works by blocking these receptors, which may reduce symptoms like nausea, often induced by chemotherapy or other treatments. Research into its efficacy and safety is ongoing, with potential applications in both gastrointestinal and neuropsychiatric disorders.
Catalog Number | I027325 |
CAS Number | 84475-07-0 |
Synonyms | Fce 22250; Fce-22250; Fce22250 |
Molecular Formula | C44H58N4O12 |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21E)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-26-[(Z)-[(E)-piperidin-1-ylmethylidenehydrazinylidene]methyl]-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
InChI | InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,50-54H,10-12,17-18H2,1-9H3,(H,47,56)/b14-13+,19-16+,23-15+,45-20-,46-21+/t22-,24+,25+,26+,30-,35-,36+,40+,44-/m0/s1 |
InChIKey | JEGGQYICWGMXOZ-FZMNFFEUSA-N |
SMILES | C[C@H]1/C=C/C=C(/C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N\N=C\N5CCCCC5)\C |